International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman diseaseFrits van Rhee, David C. Fajgenbaum, Peter M. Voorhees et al.|Blood|2018Cited by 421
International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman diseaseFrits van Rhee, David C. Fajgenbaum, Éric Oksenhendler et al.|Blood Advances|2020Cited by 218
Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 StudyTaofeek K. Owonikoko, Suresh S. Ramalingam, Suzanne E. Dahlberg et al.|Journal of Clinical Oncology|2018Cited by 193
ACCELERATE: A Patient-Powered Natural History Study Design Enabling Clinical and Therapeutic Discoveries in a Rare DisorderSheila K. Pierson, David C. Fajgenbaum, Johnson S. Khor et al.|Cell Reports Medicine|2020Cited by 33
Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman diseaseDavid C. Fajgenbaum, David Wu, Aaron M. Goodman et al.|American Journal of Hematology|2020Cited by 32